Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Chronic Myeloid Leukemia Clinical Trials

A listing of Chronic Myeloid Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (18) clinical trials

A Phase 1 clinical study for patients with childhood ALL, Acute myeloid leukemia, Preleukemia, Chronic myeloid leukemia, MYELODYSPLASTIC SYNDROME

This will be a Phase 1, open-label study of DS-3032b to assess its safety and tolerability and identify a Maximum Tolerated Dose (MTD)/tentative Recommended Phase II Dose (RP2D) in subjects with refractory or relapsed Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) in blast phase, or ...


Patients are needed to participate in a clinical research study to evaluate B-cell Acute Lymphoblastic Leukemia, Acute myeloid leukemia, Chronic Myeloid Leukemia, Blast Crisis, Blastic Plasmacytoid Dendritic Cell Neoplasm

The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of XmAb14045 and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions.


A clinical trial seeking patients for a research study for the treatment of Blood disorder, Multiple Myeloma, MYELODYSPLASTIC SYNDROME, MYELOPROLIFERATIVE DISORDER, Lymphoma, Preleukemia

Patients with malignant and non-malignant hematologic diseases including severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome (MDS), acute and chronic leukemias, Hodgkin's and non-Hodgkin's lymphoma and multiple myeloma (MM) can now be cured by allogeneic bone marrow transplantation (BMT). This curative effect has been ascribed to the use ...


A clinical trial sponsored by Sidney Kimmel Comprehensive Cancer Center for a research study for the treatment of ESSENTIAL THROMBOCYTHEMIA, Prolymphocytic Leukemia, Chronic Myeloproliferative Disorders, Plasma Cell Neoplasm, Multiple Myeloma, Polycythemia Vera, Monoclonal gammopathy, Chronic myelomonocytic leukemia, Chronic Lymphocytic Leukemia, MYELODYSPLASTIC SYNDROME, Plasma cell leukemia, Chronic myeloid leukemia, Myelosclerosis with myeloid metaplasia, Preleukemia

The main goal is to learn whether a drug called tacrolimus, which is an immune-lowering drug (an immunosuppressant) given after transplant to help prevent certain complications, can be given safely for a shorter period of time than it has been in the past. The experiences with immunosuppression duration with other ...


A clinical trial to evaluate treatments using bosutinib for patients with Chronic myeloid leukemia

The objective of the study is to provide long term access to bosutinib treatment and assess long term safety, tolerability and duration of clinical benefit, without any formal hypothesis testing; therefore, there is no formal primary endpoint.

Phase N/A

A clinical trial to evaluate treatments for patients with Chronic Myelomonocytic Leukemia in Remission, Graft-Versus-Host Disease, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Multiple Myeloma, Acute Myeloid Leukemia in Remission, Waldenstrom's Macroglobulinemia, Severe Aplastic Anemia, Hodgkin's Disease, MYELODYSPLASTIC SYNDROME, Minimal Residual Disease, MYELOPROLIFERATIVE DISORDER, Lymphoma, Preleukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission

PRIMARY OBJECTIVES: I. To determine the cumulative incidence of extensive chronic graft versus host disease (GVHD) at 1 year after transplantation utilizing the novel conditioning/GVHD prophylactic regimen for patients undergoing allogeneic hematopoietic cell transplantation, in patients who do not progress before day 100. SECONDARY OBJECTIVES: I. To evaluate clinical response, ...


A clinical trial seeking patients for a research study for the treatment of Recurrent Mycosis Fungoides/Sezary Syndrome, ESSENTIAL THROMBOCYTHEMIA, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Lymphoblastic Lymphoma, Refractory Cytopenia With Multilineage Dysplasia, anaplastic large cell lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Refractory Anemia with Excess of Blasts, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Waldenstrom's Macroglobulinemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Childhood Myelodysplastic Syndromes, Recurrent Childhood Acute Myeloid Leukemia, chronic phase chronic myelogenous leukemia, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Relapsing Chronic Myelogenous Leukemia, Chronic myelomonocytic leukemia, Recurrent Adult T-cell Leukemia/Lymphoma, de Novo Myelodysplastic Syndromes, Childhood Chronic Myelogenous Leukemia, Myelosclerosis with myeloid metaplasia, Testicular Lymphoma, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Intraocular Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Secondary Acute Myeloid Leukemia, Hepatosplenic T-cell Lymphoma, Polycythemia Vera, Blast Crisis, T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA, Angioimmunoblastic Lymphadenopathy, Refractory Hairy Cell Leukemia, Refractory Anemia With Excess Blasts in Transformation, Refractory Multiple Myeloma, Recurrent Small Lymphocytic Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Noncutaneous Extranodal Lymphoma, Juvenile Myelomonocytic Leukemia, MALT Lymphoma, Adult Acute Myeloid Leukemia With Del(5q), Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Acute Lymphoblastic Leukemia in Remission, Post-transplant Lymphoproliferative Disorder, Small Intestine Lymphoma, Previously Treated Myelodysplastic Syndromes, Recurrent/Refractory Childhood Hodgkin Lymphoma, Childhood Burkitt Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Nodal Marginal Zone B-cell Lymphoma, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

PRIMARY OBJECTIVE: To compare the rate of disease-free survival (DFS) at 1 year post hematopoietic stem cell transplant (HSCT) in patients undergoing HSCT treated on this successor Thomas Jefferson University (TJU) 2 Step reduced intensity conditioning (RIC) haploidentical regimen and compare it with that of the initial 2 Step RIC ...


A clinical trial to evaluate treatments for patients with Aplastic Anemia, MYELODYSPLASTIC SYNDROME, Lymphoma, Preleukemia, leukemia

Background The requirement for licensure of human cell and blood products became part of the FDA final rules for Human Cells, Tissues, and Tissue-Based Products (HCT/Ps) (March 29, 2004 and May 25, 2005) in an effort to prevent transmission of communicable disease, minimize contamination and preserved integrity and function during ...